Silence Therapeutics leaps as it enters up to $400 million collaboration with AstraZeneca

25 March 2020

UK novel RNA therapeutics specialist Silence Therapeutics (AIM: SLN) saw its sales rocket 32% to 535.00 pence as markets opened today, as it announced a strategic collaboration with AstraZeneca (LSE: AZN) to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for cardiovascular, renal, metabolic and respiratory diseases.

The accord draws on Silence’s extensive experience in the discovery, development and delivery of siRNA therapeutics together with Anglo-Swedish major AstraZeneca’s industry leading expertise in disease biology and target identification with the aim of developing first-in-class and differentiated therapeutics to address significant unmet need.

$80 million upfront

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK